Welcome to Critical Mass, Law.com’s weekly briefing for class action and mass tort attorneys. It’s been quite the week for lawsuits over opioids. First, talks over a potential $48 billion global settlement broke down on Friday. Then, there was the first jury trial over the opioid crisis that, well, didn’t happen. Instead, AmerisourceBergen, Cardinal Health and McKesson, the three major distributors of opiate pharmaceuticals, and one manufacturer, Teva Pharmaceuticals, agreed to a $260 million settlement with two Ohio counties just hours before opening statements on Monday. Later that day, Pennsylvania’s AG announced the $48 billion deal went through—this time, without all the cities and counties on board. I was in Cleveland on Monday and talked to some of the lawyers who were there. For this week’s Critical Mass, I’ve got more on what’s happening with the opioid cases. As always, please feel free to email me at [email protected], or follow me on Twitter: @abronstadlaw.
Mark Lanier of The Lanier Law Firm
What Jurors Were Going to Hear
I spoke with Mark Lanier (The Lanier Law Firm), who really wanted to talk about the opening statement he had planned for Monday’s opioid trial. He told me he was on “four hours a night” of sleep for the past month. After a quick celebration of his 59th birthday on Sunday in Houston, he flew out to Cleveland, where he went over the 150 slides with his trial team at the Ritz Carlton.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]